This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
End Stage Renal Disease
and you are
over 18
years old
-
The phase for this study is not defined.
Show me locations

The purpose

Design: Prospective randomised cross-over study. Fifty-two eligible patients will be randomised to a treatment time of either 6 hours or 4 hours for a period of 24 weeks and following a washout period of 4 weeks, switch to the alternative treatment time for an additional 24 weeks. Aims: To examine the feasibility and effect of extended dialysis treatment time, 6 hours thrice weekly, versus the standard, 4 hours thrice weekly, comparing the differences from baseline in outcome measures over a total 12-month period. Primary outcome measure 1]Serum albumin Secondary outcome measures Nutritional status 1. Malnutrition-inflammation score 2. Dietary intake 3. Hand-Grip strength 4. Energy expenditure Quality of life 1. Patient reported quality of life and 2. time to recovery from dialysis Serum biomarkers 1. BNP 2. Troponin 3. MCP-1 Others 24- hour Ambulatory blood pressure 24-hour accelerometer Population: Local haemodialysis population of 1200 patients Eligibility: Minimum 90days on haemodialysis treatment Duration: Fifty-six weeks

Provided treatments

  • Other: extended treatment time
  • Other: Standard treatment time

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01721421. The sponsor of the trial is Imperial College London and it is looking for 52 volunteers for the current phase.
Official trial title:
Feasibility and Physiological and Nutritional Effects of Extended Treatment Duration in Patients With End-stage Renal Disease on Haemodialysis